Superficial abrasion wounds
Conditions
Interventions
In this randomized, self-controlled trial, participants with at least two superficial abrasion wounds (1-3 cm) on opposite sides of the body receive two treatments. One wound is treated with a pyroxyl
Sponsors
KOBAYASHI Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Healthy males and females aged between 21 and 64 years old. 2. Have 2 or more abrasions that occurred within one day (equivalent to Stage I of StatPearls Wound Assessment), with at least one on each side of the upper or lower extremities. 3. Have a fresh superficial wound with a wound surface area of 1-3 cm (inclusive) in diameter (corresponding to an area of 0.79-7.07cm2). Wounds need to have a moist surface, with no visible bleeding or mild visible bleeding, and not yet have formed a crust or scab. 4. Recommended to use liquid bandage or adhesive bandage as per routine clinical practice.
Exclusion criteria
Exclusion criteria: 1. Individuals suffering from or currently being treated for serious diseases such as diabetes, cancer, kidney disease, liver disease, thyroid disease, adrenal disease, or metabolic diseases that may significantly affect the healing process, or those with a history of such conditions. 2. Individuals suffering from or currently being treated for chronic bedsores, immune disorders, infections that may affect the healing process, or those with a history of such conditions. 3. Individuals who routinely consume collagen peptides. 4. Individuals with Fitzpatrick Classification skin types V - VI (due to higher susceptibility to keloids and hypertrophic scars). 5. Individuals with acne, sunburn, eczema, scars, excessive hair, acute skin infections, hyperpigmentation, hypopigmentation, or tattoos near the target wound. 6. Pregnant or breastfeeding individuals, those who may be pregnant, or those planning to become pregnant. 7. Individuals currently participating in, or who have participated in, clinical trials related to wound care or wound healing within the past 3 months. 8. Individual deemed unsuitable for this study by the Principal Investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Wound area | — |
Secondary
| Measure | Time frame |
|---|---|
| Scar quality | — |
Countries
Asia(except Japan)
Contacts
Public ContactShota Kajiyama
KOBAYASHI Pharmaceutical Co., Ltd. Life Science Research Department R&D Headquarters
Outcome results
None listed